DN02 is a selective probe of BRD8 bromodomain family. It exhibits potency against BRD8(1) with a Kd of 32 nM, and interestingly, demonstrated this activity to be selective over BRD8’s second bromodomain (BRD8(2) with a Kd of >1000 nM)

DN02 is a selective probe of BRD8 bromodomain family. It exhibits potency against BRD8(1) with a Kd of 32 nM, and interestingly, demonstrated this activity to be selective over BRD8’s second bromodomain (BRD8(2) with a Kd of >1000 nM)

Tinlorafenib (PF-07284890, ARRY-461) is a potent, brain-penetrant inhibitor of BRAF targeting V600E/V600K mutations with IC50 values of 4.25 nM and 2.7 nM, respectively. It also effectively inhibits ERK phosphorylation and represents a new class of selective BRAF inhibitors for brain tumors.

Tinlorafenib (PF-07284890, ARRY-461) is a potent, brain-penetrant inhibitor of BRAF targeting V600E/V600K mutations with IC50 values of 4.25 nM and 2.7 nM, respectively. It also effectively inhibits ERK phosphorylation and represents a new class of selective BRAF inhibitors for brain tumors.

DN02 is a selective probe of BRD8 bromodomain family. It exhibits potency against BRD8(1) with a Kd of 32 nM, and interestingly, demonstrated this activity to be selective over BRD8’s second bromodomain (BRD8(2) with a Kd of >1000 nM)

Tinlorafenib (PF-07284890, ARRY-461) is a potent, brain-penetrant inhibitor of BRAF targeting V600E/V600K mutations with IC50 values of 4.25 nM and 2.7 nM, respectively. It also effectively inhibits ERK phosphorylation and represents a new class of selective BRAF inhibitors for brain tumors.

Glecirasib (JAB-21822, KRAS G12C inhibitor 36) is a potent, and highly selective, covalent inhibitor of KRAS G12C. It exhibits promising anti-tumor activity in KRAS G12C-mutated pancreatic ductal adenocarcinoma (PDAC) , Non-Small Cell Lung Cancer(NSCLC), Colorectal Cancer (CRC) and other solid tumors.

Tinlorafenib (PF-07284890, ARRY-461) is a potent, brain-penetrant inhibitor of BRAF targeting V600E/V600K mutations with IC50 values of 4.25 nM and 2.7 nM, respectively. It also effectively inhibits ERK phosphorylation and represents a new class of selective BRAF inhibitors for brain tumors.

Glecirasib (JAB-21822, KRAS G12C inhibitor 36) is a potent, and highly selective, covalent inhibitor of KRAS G12C. It exhibits promising anti-tumor activity in KRAS G12C-mutated pancreatic ductal adenocarcinoma (PDAC) , Non-Small Cell Lung Cancer(NSCLC), Colorectal Cancer (CRC) and other solid tumors.

Glecirasib (JAB-21822, KRAS G12C inhibitor 36) is a potent, and highly selective, covalent inhibitor of KRAS G12C. It exhibits promising anti-tumor activity in KRAS G12C-mutated pancreatic ductal adenocarcinoma (PDAC) , Non-Small Cell Lung Cancer(NSCLC), Colorectal Cancer (CRC) and other solid tumors.